<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134409">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01809379</url>
  </required_header>
  <id_info>
    <org_study_id>PIPAC-OV1</org_study_id>
    <nct_id>NCT01809379</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer</brief_title>
  <official_title>Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to assess efficacy and safety of an intraperitoneal, aerosol, high-pressure
      chemotherapy in women with recurrent ovarian cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to investigate the therapeutic efficacy of PIPAC using doxorubicin and
      cisplatin in women with recurrent ovarian cancer and disease progression with peritoneal
      carcinomatosis. The primary objective of this study is to determine the Clinical Benefit
      Rate (CBR) according to RECIST criteria   after three cycles of PIPAC with cisplatin and
      doxorubicin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The clinical benefit rate comprises complete remission, partial remission, and stable disease according to RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>left heart ejection fraction, neurological status, laparoscopy complications intraoperative, laparoscopy complications postoperative until hospital discharge, re-admission to hospital, death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>tumor apoptosis assessment, videolaparoscopy assessment of response, CA 125 assessment of response</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>various measures of response to therapy on the clinical, biochemical, and histological level</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Recurrent Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>intraperitoneal chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy with doxorubicin and cisplatin</intervention_name>
    <description>intraperitoneal chemotherapy applied as an aerosol and under pressure</description>
    <arm_group_label>intraperitoneal chemotherapy</arm_group_label>
    <other_name>CISPLATIN Teva, Adrimedac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 2 lines of previous chemotherapy

          -  recurrent ovarian cancer

          -  patient is mobile

          -  informed consent

        Exclusion Criteria:

          -  ileus

          -  necessity of parenteral nutrition
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clemens Tempfer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Runr University Bochum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clemens Tempfer, MD</last_name>
    <phone>+49 2323 499</phone>
    <phone_ext>1801</phone_ext>
    <email>clemens.tempfer@marienhospital-herne.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruhr University Bochum</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Tempfer, MD</last_name>
      <phone>+49 2323 499</phone>
      <phone_ext>1801</phone_ext>
      <email>clemens.tempfer@marienhospital-herne.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>March 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>Clemens Tempfer</investigator_full_name>
    <investigator_title>Prof. Dr. med. Clemens Tempfer, MBA</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer, recurrent, chemotherapy, intraperitoneal</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
